Oakwood Laboratories
Oakwood Laboratories is an Ohio specialist in long-acting injectable microspheres whose leuprolide depot formulations for prostate cancer went through the phase 3 trials it led.
Overview
Oakwood Laboratories, founded in 1997 in Oakwood Village, Ohio, develops sustained-release injectable microsphere formulations. Its leuprolide acetate depot products for advanced prostate cancer, developed to match the established monthly and three-monthly injections, were taken through phase 3 trials registered on ClinicalTrials.gov under Oakwood as lead sponsor, and the company also contract-manufactures depots for partners.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +6
- registry trials +8
Similar pages
not linked directly; found by shared links- CompanyForesee Pharmaceuticals
Shares Leuprolide (leuprorelin) and GnRH agonists, Pivotal (registrational) trial, Clinical trial, Prostate cancer and the tag ctgov-sponsor.
- CompanyBavarian Nordic
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer and the tag ctgov-sponsor.
- CompanyFutureChem
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer and the tag ctgov-sponsor.
- CompanyHinova Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer and the tag ctgov-sponsor.
- CompanySpectraCure
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer and the tag ctgov-sponsor.
- CompanyActive Biotech
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer and the tag ctgov-sponsor.
- CompanyABX advanced biochemical compounds
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.